Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.

@article{Hickey2009TranscutaneousIW,
  title={Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.},
  author={Danica K Hickey and Frank E. Aldwell and Kenneth W. Beagley},
  journal={Vaccine},
  year={2009},
  volume={27 44},
  pages={6217-25}
}
Mucosal adjuvants are important to overcome the state of immune tolerance normally associated with mucosal delivery and to enhance adaptive immunity to often-weakly immunogenic subunit vaccine antigens. Unfortunately, adverse side effects of many experimental adjuvants limit the number of adjuvants approved for vaccination. Lipid C is a novel, non-toxic, lipid oral vaccine-delivery formulation, developed originally for oral delivery of the live Mycobacterium bovis Bacille Calmette-Guerin (BCG… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Mucosal immune responses induced by transcutaneous vaccines.

Current topics in microbiology and immunology • 2012
View 13 Excerpts
Highly Influenced

Non-invasive epicutaneous vaccine against Respiratory Syncytial Virus: Preclinical proof of concept.

Journal of controlled release : official journal of the Controlled Release Society • 2016

Similar Papers

Loading similar papers…